So far, stroke genetics has the reputation of daunting complexity and heterogeneity. However, progress through efforts at studying the human genome has provided novel technologies and focus, and 12 stroke genes or loci have already been identified in the last years, usually through the study of large pedigrees. However, particularly little is known about the ischemic form of stroke, and only recently could one chromosomal locus be shown to exert a major effect on stroke latency and outcome – through QTL studies in mouse strains. Whether the outstanding role of this one gene locus is also true in humans should be tested in linkage analyses of large pedigrees. The characterization of such families will probably be essential for progress in molecular genetics of ischemic stroke as well as being a challenge for clinical stroke centers.

1.
Agerholm-Larsen B, et al: ACE gene polymorphism as a risk factor for ischemic cerebrovascular disease. Ann Intern Med 1997;127:346–355.
2.
Alberts MJ: Genetic aspects of cerebrovascular disease. Stroke 1991;22:276–280.
3.
Biervert C, et al: A potassium channel mutation in neonatal human epilepsy. Science 1998;279:403–406.
4.
Blackwood DH, et al: A locus for bipolar affective disorder on chromosome 4p. Nat Genet 1996;12:427–430.
5.
Brand E, et al: Evaluation of the angiotensinogen locus in human essential hypertension: A European study. Hypertension 1998;31:725–729.
6.
Brass LM, et al: Family history in patients with transient ischemic attacks. Stroke 1991;22:837–841.
7.
Brass LM, et al: A study of twins and stroke. Stroke 1992;23:221–223.
8.
Brown DM, et al: Renal disease susceptibility and hypertension are under independent genetic control in the fawn-hooded rat. Nat Genet 1996;12:44–51.
9.
Chagnon YC, et al: The human obesity gene map: The 1997 update. Obes Res 1998;6:76–92.
10.
Cruts M, et al: The presenilin genes: A new gene family involved in Alzheimer disease pathology. Hum Mol Genet 1996;5:1449–1455.
11.
Cruz-Coke R: The genes of human hypertension. Rev Med Chil 1997;125:351–357.
12.
Dietz HC, et al: Marfan syndrome caused by a recurrent de novo missense mutation in the fibrillin gene. Nature 1991;352:337–339.
13.
Ducros A, et al: Mapping of a second locus for familial hemiplegic migraine to 1q21-q23 and evidence of further heterogeneity. Ann Neurol 1997;42:885–890.
14.
Freimer NB, et al: Genetic mapping using haplotype, association and linkage methods suggests a locus for severe bipolar disorder (BPI) at 18q22–q23. Nat Genet 1996;12:436–441.
15.
Gardner K, et al: A new locus for hemiplegic migraine maps to chromosome 1q31. Neurology 1997;49:1231–1238.
16.
Gispert S, et al: Chromosomal assignment of the second (Cuban) locus for autosomal dominant cerebellar ataxia (SCA2) to human chromosome 12q23–24.1. Nature Genet 1993;4:295–299.
17.
Graeber MB, et al: Recent developments in the molecular genetics of mitochondrial disorders. J Neurol Sci 1998;153:251–263.
18.
Gunel M, et al: Mapping a gene causing cerebral cavernous malformation to 7q11.2–q21. Proc Natl Acad Sci USA 1995;92:6620–6624.
19.
Gunel M, et al: A founder mutation as a cause of cerebral cavernous malformation in Hispanic Americans. N Engl J Med 1996;334:946–951.
20.
Gunel M, Lifton RP: Counting strokes. Nat Genet 1996;13:384–385.
21.
Hendriks L, et al: Presenile dementia and cerebral haemorrhage linked to a mutation at codon 692 of the beta-amyloid precursor protein gene. Nat Genet 1992;1:218–221.
22.
Jeffs B, et al: Sensitivity to cerebral ischaemic insult in a rat model of stroke is determined by a single genetic locus. Nat Genet 1997;6:364–367.
23.
Johnson DW, et al: Mutations in the activin receptor-like kinase 1 gene in hereditary haemorrhagic telangiectasia type 2. Nat Genet 1996;13:189–195.
24.
Joutel A, et al: A gene for familial hemiplegic migraine maps to chromosome 19. Nat Genet 1993;5:40–45.
25.
Joutel A, et al: Notch3 mutations in CADASIL, a hereditary adult-onset condition causing stroke and dementia. Nature 1996;383:707–710.
26.
Joutel A, et al: Strong clustering and stereotyped nature of Notch3 mutations in CADASIL patients. Lancet 1997;350:1511–1515.
27.
Kiely DK, et al: Familial aggregation of stroke. The Framingham Study. Stroke 1993;24:1366–1371.
28.
Kobayashi Y, et al: Respiration-deficient cells are caused by a single point mutation in the mitochondrial tRNA-Leu (UUR) gene in mitochondrial myopathy, encephalopathy, lactic acidosis, and strokelike episodes (MELAS). Am J Hum Genet 1991;49:590–599.
29.
Leube B, et al: Idiopathic torsion dystonia: Assignment of a gene to chromosome 18p in a German family with adult onset, autosomal dominant inheritance and purely focal distribution. Hum Mol Genet 1996;5:1673–1677.
30.
Levy E, et al: Mutation of the Alzheimer’s disease amyloid gene in hereditary cerebral hemorrhage, Dutch type. Science 1990;248:1124–1126.
31.
Lifton RP: Genetic determinants of human hypertension. Proc Natl Acad Sci USA 1995;92:8545–8551.
32.
Lifton RP: Molecular genetics of human blood pressure variation. Science 1996;272:676–680.
33.
MacMahon S, et al: Blood pressure, stroke, and coronary heart disease. 1. Prolonged differences in blood pressure: Prospective observational studies corrected for the regression dilution bias. Lancet 1990;335:765–774.
34.
McAllistar KA, et al: Endoglin, a TGF-beta binding protein of endothelial cells, is the gene for hereditary haemorrhagic telangiectasia type 1. Nat Genet 1994;8:345–351.
35.
Ophoff RA, et al: Familial hemiplegic migraine and episodic ataxia type-2 are caused by mutations in the Ca2+ channel gene CACNL1A4. Cell 1996;87:543–552.
36.
Palsdottir A, et al: Mutation in cystatin C gene causes hereditary brain haemorrhage. Lancet 1988;ii:603–604.
37.
Polymeropoulos MH, et al: Mutation in the alpha-synuclein gene identified in families with Parkinson’s disease. Science 1997;276:2045–2047.
38.
Qian F, et al: PKD1 interacts with PKD2 through a probable coiled-coil domain. Nat Genet 1997;16:179–183.
39.
Rubattu S, et al: Chromosomal mapping of quantitative trait loci contributing to stroke in a rat model of complex human disease. Nat Genet 1996;13:429–434.
40.
Siffert W, et al: Association of a human G-protein beta3 subunit variant with hypertension. Nat Genet 1998;18:45–48.
41.
Slooter AJ, et al: Apolipoprotein E epsilon4 and the risk of dementia with stroke. A population-based investigation. JAMA 1997;277:818–821.
42.
Steinlein OK, et al: A missense mutation in the neuronal nicotinic acetylcholine receptor alpha 4 subunit is associated with autosomal dominant nocturnal frontal lobe epilepsy. Nat Genet 1995;11:201–203.
43.
Superti-Furga A, et al: Ehlers-Danlos syndrome type IV: A multi-exon deletion in one of the two COL3A1 alleles affecting structure, stability, and processing of type III procollagen. J Biol Chem 1988;263:6226–6232.
44.
Tiret L, et al: Gene polymorphisms of the renin-angiotensin system in relation to hypertension and parental history of myocardial infarction and stroke: the PEGASE study. Project d’Etude des Genes de l’Hypertension Arterielle Severe a moderee Essentielle. J Hypertens 1998;16:37–44.
45.
The European Polycystic Kidney Disease Consortium: The polycystic kidney disease 1 gene encodes a 14 kb transcript and lies within a duplicated region on chromosome 16. Cell 1994;77:881–894.
46.
Tournier-Lasserve E, et al: Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy maps to chromosome 19q12. Nat Genet 1993;3:256–259.
47.
Uwabo J, et al: Association of a variable number of tandem repeats in the endothelial constitutive nitric oxide synthase gene with essential hypertension in Japanese. Am J Hypertens 1998;11:125–128.
48.
Welin L, et al: Analysis of risk factors for stroke in a cohort of men born in 1913. N Engl J Med 1987;317:521–526.
49.
Wickelgren I: Heat shock protein linked to stroke protection. Science 1997;278:1405.
50.
Yang G, et al: C57BL/6 strain is most susceptible to cerebral ischemia following bilateral common carotid occlusion among seven mouse strains: Selective neuronal death in the murine transient forebrain ischemia. Brain Res 1997;752:209–218.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.